This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cleare, A. J. Articles by O’Keane, V. Search for Related Content PubMed PubMed Citation Articles by Cleare, A. J. Articles by O’Keane, V. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Chronic Fatigue Syndrome Hazardous Substances DB FENFLURAMINE HYDROCORTISONE

Hypothalamo-Pituitary-Adrenal Axis Dysfunction in Chronic Fatigue Syndrome, and the Effects of Low-Dose Hydrocortisone Therapy

Department of Psychological Medicine (A.J.C.), Institute of Psychiatry and Guy’s, King’s and St Thomas’ School of Medicine, London SE5 8AZ, United Kingdom; Department of Medicine (J.M., S.S., L.Y.), Guy’s, King’s and St Thomas’ School of Medicine, London SE5 9RS, United Kingdom; Department of Liaison Psychiatry (E.H., G.S.M., V.O.), Addenbrooke’s Hospital, Cambridge, Cambridgeshire CB2 2QQ, United Kingdom; and Psychiatric Unit (V.O.), Beaumont Hospital, Dublin 9, Ireland

Address all correspondence and requests for reprints to: Dr. Anthony Cleare, Department of Psychological Medicine, Institute of Psychiatry and Guy’s, King’s and St Thomas’ School of Medicine, 103 Denmark Hill, London SE5 9AZ, United Kingdom. E-mail: a.cleare{at}iop.kcl.ac.uk

Abstract

These neuroendocrine studies were part of a series of studies testing the hypotheses that 1) there may be reduced activity of the hypothalamic-pituitary-adrenal axis in chronic fatigue syndrome and 2) low-dose augmentation with hydrocortisone therapy would improve the core symptoms. We measured ACTH and cortisol responses to human CRH, the insulin stress test, and D-fenfluramine in 37 medication-free patients with CDC-defined chronic fatigue syndrome but no comorbid psychiatric disorders and 28 healthy controls. We also measured 24-h urinary free cortisol in both groups. All patients (n = 37) had a pituitary challenge test (human CRH) and a hypothalamic challenge test [either the insulin stress test (n = 16) or D-fenfluramine (n = 21)]. Baseline cortisol concentrations were significantly raised in the chronic fatigue syndrome group for the human CRH test only. Baseline ACTH concentrations did not differ between groups for any test. ACTH responses to human CRH, the insulin stress test, and D- fenfluramine were similar for patient and control groups. Cortisol responses to the insulin stress test did not differ between groups, but there was a trend for cortisol responses both to human CRH and D-fenfluramine to be lower in the chronic fatigue syndrome group. These differences were significant when ACTH responses were controlled. Urinary free cortisol levels were lower in the chronic fatigue syndrome group compared with the healthy group. These results indicate that ACTH responses to pituitary and hypothalamic challenges are intact in chronic fatigue syndrome and do not support previous findings of reduced central responses in hypothalamic-pituitary-adrenal axis function or the hypothesis of abnormal CRH secretion in chronic fatigue syndrome. These data further suggest that the hypocortisolism found in chronic fatigue syndrome may be secondary to reduced adrenal gland output.

Thirty-two patients were treated with a low-dose hydrocortisone regime in a double-blind, placebo-controlled cross-over design, with 28 days on each treatment. They underwent repeated 24-h urinary free cortisol collections, a human CRH test, and an insulin stress test after both active and placebo arms of treatment. Looking at all subjects, 24-h urinary free cortisol was higher after active compared with placebo treatments, but 0900-h cortisol levels and the ACTH and cortisol responses to human CRH and the insulin stress test did not differ. However, a differential effect was seen in those patients who responded to active treatment (defined as a reduction in fatigue score to the median population level or less). In this group, there was a significant increase in the cortisol response to human CRH, which reversed the previously observed blunted responses seen in these patients. We conclude that the improvement in fatigue seen in some patients with chronic fatigue syndrome during hydrocortisone treatment is accompanied by a reversal of the blunted cortisol responses to human CRH.

This article has been cited by other articles:

				U. M. Nater, L. S. Youngblood, J. F. Jones, E. R. Unger, A. H. Miller, W. C. Reeves, and C. Heim Alterations in Diurnal Salivary Cortisol Rhythm in a Population-Based Sample of Cases With Chronic Fatigue Syndrome Psychosom Med, April 1, 2008; 70(3): 298 - 305. [Abstract] [Full Text] [PDF]

				B. Van Houdenhove, L. Verheyen, K. Pardaens, P. Luyten, and P. Van Wambeke Rehabilitation of decreased motor performance in patients with chronic fatigue syndrome: should we treat low effort capacity or reduced effort tolerance? Clinical Rehabilitation, December 1, 2007; 21(12): 1121 - 1142. [Abstract] [PDF]

				J. L. Ryan, J. K. Carroll, E. P. Ryan, K. M. Mustian, K. Fiscella, and G. R. Morrow Mechanisms of Cancer-Related Fatigue Oncologist, May 1, 2007; 12(suppl_1): 22 - 34. [Abstract] [Full Text] [PDF]

				W. K. Jerjes, N. F. Taylor, T. J. Peters, S. Wessely, and A. J. Cleare Urinary Cortisol and Cortisol Metabolite Excretion in Chronic Fatigue Syndrome Psychosom Med, July 1, 2006; 68(4): 578 - 582. [Abstract] [Full Text] [PDF]

				A. Di Giorgio, M. Hudson, W. Jerjes, and A. J. Cleare 24-Hour Pituitary and Adrenal Hormone Profiles in Chronic Fatigue Syndrome Psychosom Med, May 1, 2005; 67(3): 433 - 440. [Abstract] [Full Text] [PDF]

				J. K. Payne A Neuroendocrine-Based Regulatory Fatigue Model Biol Res Nurs, October 1, 2004; 6(2): 141 - 150. [Abstract] [PDF]

				J. Gaab, D. Huster, R. Peisen, V. Engert, V. Heitz, T. Schad, Th. Schurmeyer, and U. Ehlert Assessment of Cortisol Response With Low-Dose and High-Dose ACTH in Patients With Chronic Fatigue Syndrome and Healthy Comparison Subjects Psychosomatics, April 1, 2003; 44(2): 113 - 119. [Abstract] [Full Text] [PDF]

				A. J. Cleare The Neuroendocrinology of Chronic Fatigue Syndrome Endocr. Rev., April 1, 2003; 24(2): 236 - 252. [Abstract] [Full Text] [PDF]

				S. L. King and K. M. Hegadoren Stress Hormones: How Do They Measure Up? Biol Res Nurs, October 1, 2002; 4(2): 92 - 103. [Abstract] [PDF]

				HPA Axis Dysfunction, Hydrocortisone Treatment, and Chronic Fatigue Syndrome Journal Watch Psychiatry, November 15, 2001; 2001(1115): 2 - 2. [Full Text]